Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment

摘要: 7024 Background: Two double-blind placebo-controlled randomized multicenter trials (INTACT 1 & 2) in NSCLC failed to show survival benefit for gefitinib (‘Iressa’, ZD1839) combination with first-line platinum-based chemotherapy. However, these large studies provide an opportunity evaluate if EGFR staining is prognostic survival. Methods: Tumor biopsies (n=516) taken between diagnosis and start of therapy were assessed by immunohistochemistry using the DakoCytomation pharmDx assay™. The analysis was stratified trial performed independently patients placebo gefitinib. A restricted backwards elimination Cox regression conducted identify independent factors that statistically significant (p<0.10) also tested treatment interaction assess they served as predictive factors. Results: found 2 EGFR-based representing growth pattern percent membrane...